Phenotypic Characterization by Single-Cell Mass Cytometry of Human Intrahepatic and Peripheral NK Cells in Patients with Hepatocellular Carcinoma.
2B4
CD160
CD49a
HCC
NK cells
Siglec-10
intrahepatic lymphocytes
mass cytometory
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
14 06 2021
14 06 2021
Historique:
received:
21
04
2021
revised:
09
06
2021
accepted:
09
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
27
10
2021
Statut:
epublish
Résumé
Overall response rates of systemic therapies against advanced hepatocellular carcinoma (HCC) remain unsatisfactory. Thus, searching for new immunotherapy targets is indispensable. NK cells are crucial effectors and regulators in the tumor microenvironment and a determinant of responsiveness to checkpoint inhibitors. We revealed the landscape of NK cell phenotypes in HCC patients to find potential immunotherapy targets. Using single cell mass cytometry, we analyzed 32 surface markers on CD56
Identifiants
pubmed: 34198593
pii: cells10061495
doi: 10.3390/cells10061495
pmc: PMC8231799
pii:
doi:
Substances chimiques
Antigens, CD
0
Neoplasm Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 20fk0210045
Organisme : Japan Agency for Medical Research and Development
ID : 21fk0210094
Organisme : Japan Agency for Medical Research and Development
ID : 21fk0210055
Organisme : Grants-in-Aid for Scientific Research
ID : 19K17509
Références
Nat Med. 2018 Aug;24(8):1178-1191
pubmed: 29942093
Oncoimmunology. 2016 Dec 7;6(1):e1264562
pubmed: 28197391
Front Immunol. 2020 Jul 17;11:1324
pubmed: 32765491
Gut. 2012 Mar;61(3):427-38
pubmed: 21930732
J Immunol. 2018 Jan 1;200(1):3-22
pubmed: 29255085
J Clin Invest. 2014 Apr;124(4):1810-20
pubmed: 24569453
Cancer Res. 2018 Dec 1;78(23):6581-6593
pubmed: 30232222
Hepatology. 2013 Mar;57(3):1107-16
pubmed: 23225218
Front Immunol. 2021 Jan 25;11:586126
pubmed: 33569050
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Immunol Rev. 2006 Dec;214:56-72
pubmed: 17100876
Clin Exp Immunol. 2020 Aug;201(2):161-170
pubmed: 32319079
Hepatology. 2019 Jul;70(1):168-183
pubmed: 30411378
BMC Cancer. 2021 Mar 8;21(1):250
pubmed: 33685409
Nature. 2019 Aug;572(7769):392-396
pubmed: 31367043
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
J Exp Med. 2015 Mar 9;212(3):415-29
pubmed: 25711213
J Immunol. 2015 Mar 15;194(6):2467-71
pubmed: 25672754
Blood. 2009 Oct 29;114(18):3822-30
pubmed: 19710502
Int J Mol Sci. 2019 Aug 24;20(17):
pubmed: 31450598
J Surg Res. 2015 Mar;194(1):107-13
pubmed: 25450598
Clin Immunol. 2008 Dec;129(3):428-37
pubmed: 18824414
Gut. 2016 Dec;65(12):1998-2006
pubmed: 26674359
Oncogene. 2017 Nov 2;36(44):6143-6153
pubmed: 28692048
Cells. 2021 Mar 10;10(3):
pubmed: 33802077
J Exp Med. 1993 Sep 1;178(3):1121-6
pubmed: 7688788
Nat Rev Cancer. 2002 Nov;2(11):850-61
pubmed: 12415255
Cancer Immunol Res. 2019 Sep;7(9):1535-1546
pubmed: 31311791
Hepatology. 2009 Sep;50(3):799-807
pubmed: 19551844
Front Immunol. 2021 Feb 22;12:603133
pubmed: 33692781
Elife. 2021 Jan 28;10:
pubmed: 33507150
Mol Oncol. 2020 Oct;14(10):2546-2559
pubmed: 32799418
Ann Surg. 2014 Mar;259(3):532-42
pubmed: 23478524
Hepatology. 2019 Mar;69(3):1165-1179
pubmed: 30153337
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Front Immunol. 2016 Oct 06;7:402
pubmed: 27766097